Accelerated Early Progression of Amyotrophic Lateral Sclerosis over the COVID-19 Pandemic
During the COVID-19 pandemic and the related lockdowns, outpatient follow-up visits for patients with chronic neurological diseases have been suspended. Managing people affected by amyotrophic lateral sclerosis (ALS) has become highly complicated, leaving patients without the standard multidisciplinary follow-up. This study aimed to analyze the impact of the COVID-19 lockdown on ALS disease progression. We compared the clinical data and progression in the first year following diagnosis for patients who received ALS diagnosis during 2020 (G20, N = 34), comparing it with a group of diagnosed in 2018 (G18, N = 31). Both groups received a comparable multidisciplinary model of care in our Tertiary Expert ALS Centre, Novara, Italy. The monthly rate of ALSFRS-R decline during the lockdown was significantly increased in G20 compared to G18 (1.52 ± 2.69 vs. 0.76 ± 0.56; p-value: 0.005). In G20, 47% required non-invasive ventilation (vs. 32% of G18). Similarly, in G20, 35% of patients died vs. 19% of patients in G18 (p-value: 0.01). All results were corrected for gender, age, site of onset, and diagnostic delay. Several factors can be implicated in making ALS more severe, with a faster progression, such as reduced medical evaluations and the possibility of therapeutic changes, social isolation, and rehabilitation therapy suspension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Brain sciences - 11(2021), 10 vom: 29. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Marchi, Fabiola [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALSFRS-R |
|---|
| Anmerkungen: |
Date Revised 26.10.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/brainsci11101291 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332194973 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332194973 | ||
| 003 | DE-627 | ||
| 005 | 20231225215109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/brainsci11101291 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332194973 | ||
| 035 | |a (NLM)34679356 | ||
| 035 | |a (PII)1291 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Marchi, Fabiola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accelerated Early Progression of Amyotrophic Lateral Sclerosis over the COVID-19 Pandemic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a During the COVID-19 pandemic and the related lockdowns, outpatient follow-up visits for patients with chronic neurological diseases have been suspended. Managing people affected by amyotrophic lateral sclerosis (ALS) has become highly complicated, leaving patients without the standard multidisciplinary follow-up. This study aimed to analyze the impact of the COVID-19 lockdown on ALS disease progression. We compared the clinical data and progression in the first year following diagnosis for patients who received ALS diagnosis during 2020 (G20, N = 34), comparing it with a group of diagnosed in 2018 (G18, N = 31). Both groups received a comparable multidisciplinary model of care in our Tertiary Expert ALS Centre, Novara, Italy. The monthly rate of ALSFRS-R decline during the lockdown was significantly increased in G20 compared to G18 (1.52 ± 2.69 vs. 0.76 ± 0.56; p-value: 0.005). In G20, 47% required non-invasive ventilation (vs. 32% of G18). Similarly, in G20, 35% of patients died vs. 19% of patients in G18 (p-value: 0.01). All results were corrected for gender, age, site of onset, and diagnostic delay. Several factors can be implicated in making ALS more severe, with a faster progression, such as reduced medical evaluations and the possibility of therapeutic changes, social isolation, and rehabilitation therapy suspension | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALSFRS-R | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a amyotrophic lateral sclerosis | |
| 650 | 4 | |a motoneuron disease | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a progression | |
| 700 | 1 | |a Gallo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Sarnelli, Maria Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a De Marchi, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Saraceno, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Cantello, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzini, Letizia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain sciences |d 2011 |g 11(2021), 10 vom: 29. Sept. |w (DE-627)NLM227436393 |x 2076-3425 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:10 |g day:29 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/brainsci11101291 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 10 |b 29 |c 09 | ||